证券代码：300199 证券简称：翰宇药业 公告编号：2025-066 深圳翰宇药业股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会存在被否决议案的情况，未通过议案为：《关于董事薪 酬的议案》。 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、2025年11月17日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第十次会议审议通过《关于提请召开2025年第四次临 时股东大会的议案》，详见公司2025年11月18日在中国证监会指定信息披露 网站（http://www.cninfo.com.cn）披露的相关公告。 2025年第四次临时股东会召开的基本情况如下： 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 会议召开时间：2025年12月5日（周五）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 本次会议的召集、召开符合《公司法》《上市公司股东 ...

法律意见书 国浩律师（深圳）事务所 关于 深圳翰宇药业股份有限公司 二〇二五年第四次临时股东大会 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦·哈萨克斯坦 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambo ...

Core Viewpoint - The company has indicated that its total production capacity for peptide raw materials exceeds 5 tons, with specific annual production plans being dynamically formulated based on market and collaboration demands [1] Group 1 - The company, Hanyu Pharmaceutical, has confirmed its current production capacity for peptide raw materials is over 5 tons [1] - The annual production schedule for specific products will be determined by market conditions and collaboration needs [1]

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Market Overview - The chemical pharmaceutical sector increased by 0.16% on December 1, with Changshan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Chemical Pharmaceutical Sector - Changshan Pharmaceutical (300255) closed at 67.70, up 8.93% with a trading volume of 353,700 shares and a transaction value of 2.379 billion [1] - Laimei Pharmaceutical (300006) closed at 5.42, up 5.24% with a trading volume of 821,100 shares [1] - Oukang Pharmaceutical (920230) closed at 13.22, up 3.44% with a trading volume of 11,400 shares [1] Top Losers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 27.05, down 8.24% with a trading volume of 315,300 shares [2] - Keyuan Pharmaceutical (301281) closed at 27.96, down 4.51% with a trading volume of 44,300 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 12.17, down 4.32% with a trading volume of 864,700 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.011 billion from institutional investors, while retail investors saw a net inflow of 466 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Maiwei Bio (688062) had a net inflow of 48.528 million from institutional investors, but a net outflow of 65.659 million from retail investors [3] - Lijun Group (000513) saw a net inflow of 23.529 million from institutional investors, with a net outflow of 25.007 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 18.642 million from institutional investors, while retail investors experienced a net inflow of 10.459 million [3]

Group 1 - The core viewpoint of the news is that Hanyu Pharmaceutical has shown significant stock price fluctuations and strong financial performance in recent months, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of November 24, Hanyu Pharmaceutical's stock price increased by 2.09% to 18.11 CNY per share, with a total market capitalization of 15.996 billion CNY [1] - The company has experienced a 40.50% increase in stock price year-to-date, but has seen a decline of 6.65% in the last five trading days and 16.89% over the last 20 days [1] - For the period from January to September 2025, Hanyu Pharmaceutical achieved a revenue of 683 million CNY, representing a year-on-year growth of 82.06%, and a net profit of 71.35 million CNY, which is a 305.00% increase compared to the previous year [2] Group 3 - Hanyu Pharmaceutical has not distributed any dividends in the last three years, with a total payout of 417 million CNY since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased to 110,100, with an average of 6,771 circulating shares per person, a decrease of 42.81% from the previous period [2][3] - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 33.5479 million shares, an increase of 25.8662 million shares from the previous period [3]

Core Viewpoint - Han Yu Pharmaceutical has undergone significant management changes, appointing two new executive presidents to adapt to a complex market environment and pursue internationalization strategies [2][3][4]. Management Changes - The resignation of PINXIANG YU, the former executive president, was due to retirement, and he will not hold any positions in the company or its subsidiaries post-resignation [3]. - The board has appointed Tang Yangming and Shen Yaping as new executive presidents, with their terms lasting until the current board's term ends [3][4]. - Tang Yangming has over 20 years of experience in peptide drug research and has been with Han Yu Pharmaceutical since 2005 [3]. - Shen Yaping, an external hire, has a notable background in international business from his tenure at Jiangsu Hengrui Medicine Co., Ltd., where he held various senior roles [4]. Recent Personnel Adjustments - Han Yu Pharmaceutical has made multiple personnel adjustments in the second half of the year, affecting key positions such as vice presidents, board secretaries, and committee members [5][6]. - The company has seen a rapid succession of management changes, including the resignation of vice president Zhang Baole and board secretary Yang Di, both of whom left for personal reasons [6]. Financial Performance - In the first three quarters of the year, Han Yu Pharmaceutical reported a revenue of 683 million yuan, marking an 82.06% year-on-year increase, and a net profit of 71.35 million yuan, indicating a turnaround from losses [7]. - The company achieved an operating cash flow of 271 million yuan, a significant increase of 207.37%, setting a historical high for the same period [7].

Group 1 - The core viewpoint of the article highlights the recent management restructuring at Hanyu Pharmaceutical, indicating a shift towards a dual CEO structure with both external and internal leadership to enhance operational efficiency [2][4][6] Group 2 - The management changes began in August 2025 with the resignation of the Vice President responsible for overseas marketing, followed by further adjustments in October and November, indicating a trend of personnel turnover across key operational areas [4][6] - The adjustments cover critical management aspects including market expansion, capital market communication, and overall company operations, suggesting a comprehensive overhaul of the management structure within a short timeframe [6]

Core Insights - Shenzhen Hanyu Pharmaceutical Co., Ltd. has appointed Tang Yangming and Shen Yaping as executive presidents to enhance management structure and achieve complementary advantages [1][2] Group 1: Management Changes - Tang Yangming has over 20 years of experience in peptide drug research and has been a senior vice president at Hanyu Pharmaceutical, ensuring effective execution of company strategies [1] - Shen Yaping brings extensive experience from his tenure at Hengrui Medicine, focusing on international market strategies and commercialization, which aligns with Hanyu Pharmaceutical's expansion into overseas markets [1][2] Group 2: Strategic Implications - The addition of Shen Yaping is expected to infuse Hanyu Pharmaceutical with innovative drug development strategies, particularly in peptide drugs, enhancing clinical progression and commercialization efforts [2] - Tang Yangming's promotion reflects the company's commitment to internal talent development, ensuring continuity in core technologies and stable operations [2]

Core Viewpoint - Han Yu Pharmaceutical announced the nomination of Mr. Shen Yaping as a candidate for the sixth non-independent director [2] Group 1 - The company intends to supplement its board with a new non-independent director [2]